Postoperative gabapentinoid use is associated with improved survival in glioblastoma: A nationwide population-based study
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 16.06.2026. Verfasst von Sahin Hanalioglu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Glioblastoma (GBM) is a highly aggressive primary brain tumor that can integrate into neural circuits implicated in tumor progression and treatment resistance. Gabapentinoids are proposed to disrupt such interactions. We analyzed postoperative gabapentinoid use and overall survival (OS) in nationwide adult GBM cohort.
Methods
This retrospective population-based study utilized the Turkish national healthcare registry, identifying adult patients with pathology-confirmed GBM who underwent surgery between 2016 and 2024. The primary endpoint was OS. Stabilized inverse probability of treatment weighting (sIPTW) was applied to adjust for potential confounders, and survival associations were evaluated using multivariable Cox proportional hazards models. Survival curves were analyzed using Kaplan-Meier estimator, and statistical significance was defined as a two-sided P-value <.05.
Results
Of 11,924 patients, 701 (5.9%) utilized postoperative gabapentinoids. In sIPTW-weighted analyses, gabapentinoid utilization was associated with reduced mortality risk (HR 0.75; 95% CI, 0.66-0.84; P < .001). Age-stratified analyses demonstrated effect modification, with survival benefit observed in patients aged ≥55 years (HR 0.70; 95% CI, 0.60-0.81) but not in those <55 years. Within older subgroup, both gabapentin (n = 349; HR 0.70; 95% CI, 0.59-0.83; P < .001) and pregabalin (n = 248; HR 0.68; 95% CI, 0.56-0.83; P < .001) independently improved OS. Dose-response analyses suggested lower-mortality exposure ranges (gabapentin: 1,200-2,400 mg/day; pregabalin: >400 mg/day).
Conclusions
In this nationwide cohort, postoperative gabapentinoid use was associated with improved survival in patients with GBM, particularly aged ≥55 years. These findings support targeting neuron-glioma axis and warrant prospective evaluation of gabapentinoids as adjuvant therapies in GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- Department of Neurosurgery, Brigham and Women's Hospital, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurosurgery, University of Health Sciences Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
- General Directorate of Health Information Systems, Ministry of Health, Ankara, Turkey.
- Ministry of Health, Ankara, Turkey.
- School of Public Health, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Sahin Hanalioglu, Efecan Cekic, Egemen Gok, Beyza Turken
Zitieren
APA
Hanalioglu, S., Cekic, E., Gok, E., Turken, B., Sahin, A., Bayram, S., Ozturk, N., Ata, N., Birinci, S., Isikay, I., Claus, E., Chiocca, E. A., Hayran, M., & Bernstock, J. D. (2026). Postoperative gabapentinoid use is associated with improved survival in glioblastoma: A nationwide population-based study. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag162
Vancouver
Hanalioglu S, Cekic E, Gok E, Turken B, Sahin A, Bayram S, et al. Postoperative gabapentinoid use is associated with improved survival in glioblastoma: A nationwide population-based study. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag162
BibTeX
@article{Hanalioglu2026,
author = {Hanalioglu, Sahin and Cekic, Efecan and Gok, Egemen and Turken, Beyza and Sahin, Ayca and Bayram, Sinem and Ozturk, Neslihan and Ata, Naim and Birinci, Suayip and Isikay, Ilkay and Claus, Elizabeth and Chiocca, Ennio A and Hayran, Mutlu and Bernstock, Joshua D},
title = {Postoperative gabapentinoid use is associated with improved survival in glioblastoma: A nationwide population-based study},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag162}
}
EUVIMED